Impact of increased copayments on the discontinuation/switching rates of nonformulary medications

Journal of Pharmacy Technology

Volumn 21, Issue 3, 2005, Pages 137-143

  Nair, Kavita V ^a   Valuck, Robert J ^a   Allen, Richard R ^b   Lewis, Sonya J ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b Peak Statistical Services   (United States)

^c Anthem Prescription Management   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTIULCER AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; GOLD DERIVATIVE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROTON PUMP INHIBITOR; SALICYLIC ACID DERIVATIVE; SUCRALFATE; VASODILATOR AGENT;

ADULT; ARTICLE; CHRONIC DISEASE; COMORBIDITY; DEMOGRAPHY; DRUG COST; DRUG SUBSTITUTION; DRUG USE; FEMALE; HEALTH CARE PLANNING; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; PHARMACY; PRESCRIPTION; RETROSPECTIVE STUDY; UNITED STATES;

EID: 17744381561     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512250502100304     Document Type: Article

References (18)

1. Curtiss FR. Perspectives: drugs, PPO's, tiered cost share for beneficiaries and consumer preferences. J Manag Care Pharm 2002;8: 177-80.
2. Novartis pharmacy benefit report: facts and figures. 2001 edition. East Hanover, NJ: Novartis, 2001.
3. Drug benefit cost and plan design survey report. 2002 edition. Albuquerque, NM: Wellman Publishing, 2002.
4. Stuart B, Grana J. Ability to pay and decision to medicate. Med Care 1998;36:202-11.
5. ZIP code statistics. US Census Bureau. www.census.gov/epcd/ www/zipstats.html (accessed 2004 Oct 5).
6. Wilkins R. Use of postal codes and addresses in the analysis of health data. Health Rep 1993;5:157-77.
7. Malone DC, Billups SJ, Valuck RJ, Carter BL. Development of a chronic disease indicator score using a Veterans Affairs Medical Center medication database. J Clin Epidemiol 1999;52:551-7.
8. Malone DC, Raebel MA. Development of a chronic disease indicator using a managed care population (abstract). International Society for Pharmacoeconomics and Outcomes Research annual meeting, Arlington, VA, May 22, 2001. Value in Health 2001;4:184.
9. Fairman KA, Motheral BR. Evaluating medication adherence: which measure is right for your program? J Manag Care Pharm 2000;6:499-504.
10. Harold LR, Lessard D, Yarzebski J, Gurwitz JH, Gore JM, Goldberg RJ. Age and sex differences in the treatment of patients with initial acute myocardial infarction: a community wide perspective. Cardiology 2003;99:39-46.
11. O'Connor RM, Johannesson M, Hass SL, Knobelt-Nguyen G. Urge incontinence: quality of life and patients valuation of symptom reduction. Pharmacoeconomics 1998;14:531-9.
12. Thompson MS. Willingness to pay and accept risk to cure chronic diseases. Am J Public Health 1986;76:392-6.
13. Kleinman L, McIntosh E, Ryan M, Schmier J, Crawley J, Locke GR 3rd, et al. Willingness to pay for complete symptom relief of gastroesophaegeal reflux disease. Arch Intern Med 2002;162:1361-6.
14. Allowance plan takes new approach to drug benefits. Humana Rx Impact. www.humana.com/providers/NewsLetters/ HumanaWebSpring04/articles/ AllowancePlanTakesNew.html (accessed 2004 Oct 7).
15. Segedin DA. Three-tier copayment plans: design considerations and effectiveness. Drug Benefit Trends 1999;11:43-52.
16. Three-tier designs show mixed results. March 2002. QualityIndicator.Com. www.qualityindicator.com/cgi-bin/article.cgi?article_id= 1117 (accessed 2002 Sept 13).
17. Pauly MN. Medicare drug coverage and moral hazard. Health Aff 2004;23:113-22.
18. Mullins CD. Rising copayments and the kinked demand curve. Clin Ther 2003;25:3144-6.